March 1, 2004
Troy, N.Y. - The National Institutes of Health (NIH) has
    awarded Rensselaer Polytechnic Institute a $2.7 million,
    four-year grant to develop new tools for drug discovery. The
    grant, awarded in partnership with the University of
    California, Berkeley, Massachusetts Institute of Technology
    (MIT), and Oak Ridge National Laboratory, will support basic
    research intended to produce effective pharmaceuticals faster
    and more economically.
    
     Jonathan Dordick, the Howard P. Isermann '42 Professor of
    Chemical and Biological Engineering at Rensselaer, leads the
    research team that includes Shekhar Garde, assistant professor
    of chemical and biological engineering at Rensselaer; Alexander
    Klibanov, professor of chemistry and bioengineering at MIT;
    Douglas Clark and Jeffrey Reimer, professors of chemical
    engineering at U.C. Berkeley; and Brian Davison, director of
    life sciences at Oak Ridge.
    
     "This is a stellar partnership that relies on many different
    skill sets to complete the research," Dordick said. "Our goal
    is to develop a key set of tools to synthesize and screen
    promising compounds rapidly, and identify those most suitable
    for further development as potential new drugs." The current
    process of developing a single new therapeutic drug can take
    many years and cost up to $1.7 billion, according to a recent
    report in Chemical & Engineering News.
    
     Recent advances in chemistry and screening techniques make it
    possible to identify large numbers of promising compounds,
    known as derivative libraries. Yet the subsequent testing
    required to evaluate each compound is expensive and slow. The
    resulting bottleneck in drug development has attracted
    considerable attention among researchers seeking to advance
    more efficient and affordable processes.
    
     Dordick and the team are proposing a novel set of techniques
    that will, if successful, remove this bottleneck. "With this
    research," Dordick said, "we will be able to generate
    completely new compounds, accessing a whole new range of
    molecules and expanding molecular libraries."
    
     To produce the derivative libraries, the researchers will use
    enzymes to react with promising compounds attached to small
    beads or soluble polymer supports. Because the products of the
    enzymatic reactions remain on the bead or polymer, further
    derivatization is possible by simply washing away the initial
    reagents and adding in new ones. It is hoped this will enable
    rapid and repeated synthesis of compound derivatives. However,
    to achieve this novel synthetic strategy, Dordick and the
    research team will need to obtain a fundamental understanding
    of how enzymes function with their reactants attached to a
    bead, and then identify ways to coax enzymes into working
    better under such conditions. "Successful completion of this
    research program will result in a powerful new tool that
    biomedical investigators can use to speed the search for new,
    more potent therapeutics," Dordick said.
    
     The researchers will begin work with a series of simple
    compounds and progress to complex natural products, including
    the flavonoid bergenin, and current pharmaceuticals, including
    the current HIV-1 protease inhibitor indinavir.
    
     This award represents Rensselaer's first Bioengineering
    Research Partnership Grant from NIH. Rensselaer currently has
    30 active grants from the NIH totaling $24 million, an increase
    in five years from three active NIH grants totaling $600,000.
    The basic research supported by this grant will be carried out
    in the new Rensselaer Center for Biotechnology and
    Interdisciplinary Studies, a state-of-the-art facility
    scheduled to open in September 2004.
    
     About Biotechnology at Rensselaer
     Biotechnology research at Rensselaer comprises
    multidisciplinary work, combining life sciences, information
    science, applied mathematics, engineering, and physics. Areas
    of research include biocatalysis and metabolic engineering
    (application of enzymes and manipulated metabolic pathways);
    functional tissue engineering (creating replacement tissues and
    organs that can augment or replace damaged tissue); integrated
    systems biology (systems-based, experimental methods of gaining
    insight into the function of complex biosystems); and
    computational biology and bioinformatics (using information
    technology tools to search massive databases, such as those
    generated by the Human Genome project, to efficiently correlate
    relevant facts).
        Contact: Robert Pini
        Phone: (518) 276-6050
        E-mail: pinir@rpi.edu